Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma
Background and Aims: The prognosis of patients with advanced hepatocellular carcinoma (HCC) is expected to improve as multiple molecular target agents (MTAs) are now available. However, the impact of the availability of sequential MTAs has not been fully verified yet. Approach and Results: We retros...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2021-12-01
|
| Series: | Liver Cancer |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/519868 |
| _version_ | 1818556066318778368 |
|---|---|
| author | Kazufumi Kobayashi Sadahisa Ogasawara Aya Takahashi Yuya Seko Hidemi Unozawa Rui Sato Shunji Watanabe Michihisa Moriguchi Naoki Morimoto Satoshi Tsuchiya Kenji Iwai Masanori Inoue Keita Ogawa Takamasa Ishino Terunao Iwanaga Takafumi Sakuma Naoto Fujita Hiroaki Kanzaki Keisuke Koroki Masato Nakamura Naoya Kanogawa Soichiro Kiyono Takayuki Kondo Tomoko Saito Ryo Nakagawa Eiichiro Suzuki Yoshihiko Ooka Shingo Nakamoto Akinobu Tawada Tetsuhiro Chiba Makoto Arai Tatsuo Kanda Hitoshi Maruyama Kengo Nagashima Jun Kato Norio Isoda Takeshi Aramaki Yoshito Itoh Naoya Kato |
| author_facet | Kazufumi Kobayashi Sadahisa Ogasawara Aya Takahashi Yuya Seko Hidemi Unozawa Rui Sato Shunji Watanabe Michihisa Moriguchi Naoki Morimoto Satoshi Tsuchiya Kenji Iwai Masanori Inoue Keita Ogawa Takamasa Ishino Terunao Iwanaga Takafumi Sakuma Naoto Fujita Hiroaki Kanzaki Keisuke Koroki Masato Nakamura Naoya Kanogawa Soichiro Kiyono Takayuki Kondo Tomoko Saito Ryo Nakagawa Eiichiro Suzuki Yoshihiko Ooka Shingo Nakamoto Akinobu Tawada Tetsuhiro Chiba Makoto Arai Tatsuo Kanda Hitoshi Maruyama Kengo Nagashima Jun Kato Norio Isoda Takeshi Aramaki Yoshito Itoh Naoya Kato |
| author_sort | Kazufumi Kobayashi |
| collection | DOAJ |
| description | Background and Aims: The prognosis of patients with advanced hepatocellular carcinoma (HCC) is expected to improve as multiple molecular target agents (MTAs) are now available. However, the impact of the availability of sequential MTAs has not been fully verified yet. Approach and Results: We retrospectively collected the data on the whole clinical course of 877 patients who received any MTAs as first-line systemic therapy for advanced HCC between June 2009 and March 2019. The study population was divided into 3 groups according to the date of first-line MTA administration (period 1: 2009–2012, n = 267; period 2: 2013–2016, n = 352; period 3: 2017–2019, n = 258). Then, we compared the number of MTAs used, overall survival (OS), and MTA treatment duration among the 3 groups. Analysis was also performed separately for advanced-stage and nonadvanced-stage HCC. The proportion of patients who received multiple MTAs was remarkably increased over time (1.1%, 10.2%, and 42.6% in periods 1, 2, and 3, respectively, p < 0.001). The median OS times were prolonged to 10.4, 11.3, and 15.2 months in periods 1, 2, and 3, respectively (p = 0.016). Similarly, the MTA treatment durations were extended (2.7, 3.2, and 6.6 months in periods 1, 2, and 3, respectively; p < 0.001). We confirmed that the correlation between OS and MTA treatment duration was strengthened (period 1: 0.395, period 2: 0.505, and period 3: 0.667). All these trends were pronounced in the patients with advanced-stage HCC but limited in the patients with nonadvanced-stage HCC. Conclusions: The availability of multiple MTAs had steadily improved the prognosis of patients with advanced HCC patients, particularly advanced-stage HCC patients. |
| first_indexed | 2024-12-13T23:42:39Z |
| format | Article |
| id | doaj.art-3d27bd60476f43d0ad39fa2137391db5 |
| institution | Directory Open Access Journal |
| issn | 2235-1795 1664-5553 |
| language | English |
| last_indexed | 2024-12-13T23:42:39Z |
| publishDate | 2021-12-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Liver Cancer |
| spelling | doaj.art-3d27bd60476f43d0ad39fa2137391db52022-12-21T23:27:07ZengKarger PublishersLiver Cancer2235-17951664-55532021-12-0111310.1159/000519868519868Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular CarcinomaKazufumi Kobayashi0Sadahisa Ogasawara1https://orcid.org/0000-0002-6540-9064Aya Takahashi2Yuya Seko3Hidemi Unozawa4Rui Sato5Shunji Watanabe6Michihisa Moriguchi7Naoki Morimoto8Satoshi Tsuchiya9Kenji Iwai10Masanori Inoue11Keita Ogawa12Takamasa Ishino13Terunao Iwanaga14Takafumi Sakuma15Naoto Fujita16Hiroaki Kanzaki17Keisuke Koroki18Masato Nakamura19Naoya Kanogawa20Soichiro Kiyono21Takayuki Kondo22Tomoko Saito23Ryo Nakagawa24Eiichiro Suzuki25Yoshihiko Ooka26Shingo Nakamoto27Akinobu Tawada28Tetsuhiro Chiba29Makoto Arai30https://orcid.org/0000-0003-1061-2193Tatsuo Kanda31https://orcid.org/0000-0002-3740-5090Hitoshi Maruyama32Kengo Nagashima33https://orcid.org/0000-0003-4529-9045Jun Kato34Norio Isoda35Takeshi Aramaki36Yoshito Itoh37Naoya Kato38Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, JapanDepartment of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDivision of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, JapanDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Tochigi, JapanDepartment of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, JapanDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Tochigi, JapanDivision of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, JapanDivision of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, JapanNumazu City Hospital, Shizuoka, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanResearch Center for Medical and Health Data Science, The Institute of Statistical Mathematics, Tokyo, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Tochigi, JapanDivision of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, JapanDepartment of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, JapanDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, JapanBackground and Aims: The prognosis of patients with advanced hepatocellular carcinoma (HCC) is expected to improve as multiple molecular target agents (MTAs) are now available. However, the impact of the availability of sequential MTAs has not been fully verified yet. Approach and Results: We retrospectively collected the data on the whole clinical course of 877 patients who received any MTAs as first-line systemic therapy for advanced HCC between June 2009 and March 2019. The study population was divided into 3 groups according to the date of first-line MTA administration (period 1: 2009–2012, n = 267; period 2: 2013–2016, n = 352; period 3: 2017–2019, n = 258). Then, we compared the number of MTAs used, overall survival (OS), and MTA treatment duration among the 3 groups. Analysis was also performed separately for advanced-stage and nonadvanced-stage HCC. The proportion of patients who received multiple MTAs was remarkably increased over time (1.1%, 10.2%, and 42.6% in periods 1, 2, and 3, respectively, p < 0.001). The median OS times were prolonged to 10.4, 11.3, and 15.2 months in periods 1, 2, and 3, respectively (p = 0.016). Similarly, the MTA treatment durations were extended (2.7, 3.2, and 6.6 months in periods 1, 2, and 3, respectively; p < 0.001). We confirmed that the correlation between OS and MTA treatment duration was strengthened (period 1: 0.395, period 2: 0.505, and period 3: 0.667). All these trends were pronounced in the patients with advanced-stage HCC but limited in the patients with nonadvanced-stage HCC. Conclusions: The availability of multiple MTAs had steadily improved the prognosis of patients with advanced HCC patients, particularly advanced-stage HCC patients.https://www.karger.com/Article/FullText/519868sequential therapysorafenibregorafeniblenvatinibramucirumab |
| spellingShingle | Kazufumi Kobayashi Sadahisa Ogasawara Aya Takahashi Yuya Seko Hidemi Unozawa Rui Sato Shunji Watanabe Michihisa Moriguchi Naoki Morimoto Satoshi Tsuchiya Kenji Iwai Masanori Inoue Keita Ogawa Takamasa Ishino Terunao Iwanaga Takafumi Sakuma Naoto Fujita Hiroaki Kanzaki Keisuke Koroki Masato Nakamura Naoya Kanogawa Soichiro Kiyono Takayuki Kondo Tomoko Saito Ryo Nakagawa Eiichiro Suzuki Yoshihiko Ooka Shingo Nakamoto Akinobu Tawada Tetsuhiro Chiba Makoto Arai Tatsuo Kanda Hitoshi Maruyama Kengo Nagashima Jun Kato Norio Isoda Takeshi Aramaki Yoshito Itoh Naoya Kato Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma Liver Cancer sequential therapy sorafenib regorafenib lenvatinib ramucirumab |
| title | Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma |
| title_full | Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma |
| title_fullStr | Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma |
| title_full_unstemmed | Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma |
| title_short | Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma |
| title_sort | evolution of survival impact of molecular target agents in patients with advanced hepatocellular carcinoma |
| topic | sequential therapy sorafenib regorafenib lenvatinib ramucirumab |
| url | https://www.karger.com/Article/FullText/519868 |
| work_keys_str_mv | AT kazufumikobayashi evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT sadahisaogasawara evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT ayatakahashi evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT yuyaseko evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT hidemiunozawa evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT ruisato evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT shunjiwatanabe evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT michihisamoriguchi evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT naokimorimoto evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT satoshitsuchiya evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT kenjiiwai evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT masanoriinoue evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT keitaogawa evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT takamasaishino evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT terunaoiwanaga evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT takafumisakuma evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT naotofujita evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT hiroakikanzaki evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT keisukekoroki evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT masatonakamura evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT naoyakanogawa evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT soichirokiyono evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT takayukikondo evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT tomokosaito evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT ryonakagawa evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT eiichirosuzuki evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT yoshihikoooka evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT shingonakamoto evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT akinobutawada evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT tetsuhirochiba evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT makotoarai evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT tatsuokanda evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT hitoshimaruyama evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT kengonagashima evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT junkato evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT norioisoda evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT takeshiaramaki evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT yoshitoitoh evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma AT naoyakato evolutionofsurvivalimpactofmoleculartargetagentsinpatientswithadvancedhepatocellularcarcinoma |